A combined preparation of CJC-1295 without DAC (a GHRH analog) and Ipamorelin (a selective ghrelin-receptor agonist).
Mechanism of Action:
Pairs two distinct receptor pathways, GHRH receptor and GHS-R1a, which researchers study for complementary effects on pituitary signaling.
Research Applications:
- Dual-pathway pituitary signaling models
- Comparison with single-compound preparations
- Combination pharmacology
For laboratory research use only. Not for human or animal consumption.
CJC-1295 without DAC + Ipamorelin at a glance
| Compound type | Combined preparation: GHRH analog and ghrelin-receptor agonist |
|---|---|
| Primary research target | GHRH receptor and GHS-R1a |
| Documentation | Batch-specific Certificate of Analysis (see the COA tab) |
| Supplied for | Laboratory research use only |
Frequently asked questions
What is CJC-1295 without DAC + Ipamorelin?
A combined preparation of CJC-1295 without DAC (a GHRH analog) and Ipamorelin (a selective ghrelin-receptor agonist).
What do researchers study CJC-1295 without DAC + Ipamorelin for?
Pairs two distinct receptor pathways, GHRH receptor and GHS-R1a, which researchers study for complementary effects on pituitary signaling.
Where can I find the Certificate of Analysis?
In the COA tab on this page. Reports come from independent third-party laboratories, are tied to a specific batch, and carry a verification key that can be checked on the testing lab’s website.
Is CJC-1295 without DAC + Ipamorelin for human use?
No. Karma Research Peptides supplies CJC-1295 without DAC + Ipamorelin strictly for in-vitro laboratory research. It is not for human or animal consumption, and we do not provide dosing or human-use guidance.
